Everybody's MBA's not withstanding, just a word from the clinical arena. I do not own Fox Hollow, but am intimately familiar with the Silverhawk since I work in Vascular sales. There are several issues with Silverhawk that I will list. First and foremost, long term patency is poor with this product. A recent study cited 80% patency out to 6 months, but a dismal 20% after 6 months. This means treated vessels are not staying open and require additional therapy. The second issue is cost. Hospital administrators hate this product precisely because it is expensive and does not deliver. At this time there is no cure for intimal hyperplasia or PAD, until that occurs I believe this stock is going to be a disappointment .

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.

Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.